Simple Summary Chronic myeloid leukemia (CML) is a blood cancer. Unlike other cancers
CML treatment is lifelong and many patients experience side effects. For those patients who …

Chronic myeloid leukemia (CML) is the best example of successful targeted therapy. Today,
the overall survival of patients with CML treated by using tyrosine kinase inhibitors (TKIs) is …

In addition to the best possible overall survival, discontinuation of the tyrosine kinase-
inhibitor (TKI) treatment [treatment free remission (TFR)] without observing a recurrence of …

Clinical trials have formally demonstrated that in chronic myeloid leukemia (CML), patients
treated with tyrosine kinase inhibitors (TKI) who achieved and maintained deep molecular …

In the past few years, international treatment guidelines for chronic myeloid leukaemia have
incorporated recommendations for attempting discontinuation of treatment with tyrosine …

Introduction The treatment of chronic myeloid leukemia (CML) has been drastically changed
by the approval of tyrosine kinase inhibitors (TKIs). CML is now managed as a chronic …

Tyrosine kinase inhibitors (TKIs) represent a major breakthrough in the treatment of chronic
myeloid leukemia (CML). Thanks to these agents, CML has been transformed from a …

The dramatic success of tyrosine kinase inhibitors (TKIs) has led to the widespread
perception that chronic myeloid leukemia (CML) has become another chronic disease …

With the discovery of tyrosine kinase inhibitors (TKIs), overall survival in patients with chronic
myeloid leukemia (CML) now approaches that of the general population. While these TKIs …

Background: A new goal in treatment of chronic myeloid leukemia (CML) in patients with
stable deep molecular response (DMR) is maintaining durable treatment-free remission …